UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

January 19, 2021

Date of report (date of earliest event reported)

 

 

 

MusclePharm Corporation

(Exact name of registrant as specified in its charter)

 

 

 

Nevada   000-53166   77-0664193

(State or other jurisdictions of

incorporation or organization)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

4500 Park Granada, Suite 202, Calabasas, CA 91302

(Address of principal executive offices) (Zip Code)

 

(800) 292-3909

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrants under any of the following provisions:

 

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered

N/A

        

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

  Emerging growth company [  ]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

 

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Effective January 19, 2021, the Board of Directors (the “Board”) of MusclePharm Corporation (the “Company”) appointed Michael Heller to serve as a director until the Company’s 2021 annual meeting of stockholders or his earlier death, resignation or removal. The Company expects Mr. Heller to serve on the Board’s Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee.

 

Mr. Heller will be compensated for his service as a director in accordance with the Company’s non-employee director compensation policy. The Company plans to enter into an indemnification agreement with Mr. Heller, which will provide him with indemnification in connection with his service as a member of the Board.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  MUSCLEPHARM CORPORATION
     
  By: /s/ Ryan Drexler
  Name: Ryan Drexler
  Title: Chief Executive Officer  

 

Date: January 22, 2021

 

 

 

 

Muscle Pharm (PK) (USOTC:MSLP)
Historical Stock Chart
From Jul 2022 to Aug 2022 Click Here for more Muscle Pharm (PK) Charts.
Muscle Pharm (PK) (USOTC:MSLP)
Historical Stock Chart
From Aug 2021 to Aug 2022 Click Here for more Muscle Pharm (PK) Charts.